메뉴바로가기 본문바로가기

About

Next generation VLP-based prophylactic and therapeutic vaccines with improved efficacy and safety profile

R&D

High-yield, fast and cost-effective VLP production technology for the development of novel prophylactic and therapeutic vaccines

Recruit

Opportunities to achieve personal and professional goals as valued contributors to global public health

Notice

Received Grants of TIPS Program

 Notice that the received the TIPS program grant as follows.   Project titleTIPS ProgramPrimary organizationInThera IncDevelopment period2017.06.01. ~ 2019.05.31. Contribution from government500,000,000 KRWInvestment 100,000,000 KRW  

About

Improving Human Wellness Through Innovative Protein Biotechnology

InThera Inc. aims to develop and deliver the next generation virus-like particle (VLP)-based prophylactic and therapeutic vaccines with improved efficacy and safety profile against emerging/re-emerging viral infections of global concern.

Technology

Technology

InThera Inc. established a novel E.coli - based VLP production platform which offers an efficient, homologous, stable and highly immunogenic products and significantly reduce the scaling-up time and complexity. The endeavor will heighten the translation opportunity for unmet-need vaccines and provide the alternative means for the delivery of safer and more effective version of previously licensed vaccines

Technology

Pipeline

Through the use of our platform technology, InThera Inc. will provide more safe and innovative solutions against emerging/re-emerging viral infections.

01/ 02

R&D

Human Vaccine

Emerging viruses pose a major threat to global public health and economic burdens. And yet, the conventional cell culture often fails to develop and deliver sufficient vaccine in a timely manner. As an alternative to cell-culture based vaccine, VLPs are considered as a high priority vaccine strategy. InThera aims to develop unmet-need prophylactic and therapeutic vaccines against the emerging viral infections, in which vaccine development has been hampered due to the lack of the proper culture system for the virus of concern.

more

R&D

Animal Vaccine

In response to the strong growth and demands of veterinary vaccines for livestock and companion animal, InThera develop and delivery of more safe, effective and affordable version of previously licensed inactivated vaccines.

more